Compare Intuitive Surgical, Inc. (ISRG) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Surgical, Inc. vs Moderna, Inc. — how do they compare? Intuitive Surgical, Inc. trades at $401.01 (market cap $141.75B), while Moderna, Inc. trades at $63.61 (market cap $24.18B). The key difference: Intuitive Surgical, Inc. is far larger — about 5.9× Moderna, Inc.'s market cap, and Moderna, Inc. is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals.
| ISRG | MRNA | |
|---|---|---|
Market Cap | $141.75B | $24.18B |
Sector | Health | Health |
52-Week High | $592.85 | $81.80 |
52-Week Low | $332.02 | $22.36 |
Enterprise Value | $136.53B | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $401.46, up 2.05% today, with strong quarterly earnings beats and bullish analyst consensus. The stock shows robust revenue growth, expanding margins, and solid cash flow, supported by the da Vinci 5 system adoption. Technical indicators are mixed, with RSI signaling overbought conditions but moving averages bullish.
Outlook remains positive due to durable demand and innovation, though high valuation and competition pose risks. Upside to the $518.10 consensus target offers potential, but investors should weigh premium multiples against growth sustainability.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
